These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 24064957)

  • 41. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
    Antonarakis ES; Drake CG
    Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Fas-deficient fully allogeneic dendritic cells administered via an intratumoral injection route show efficient antitumor effects in murine models.
    Okano S; Kondoh H; Toshima T; Nakagawara H; Yoshizumi T; Soejima Y; Shirabe K; Harada M; Yoshikai Y; Maehara Y
    Fukuoka Igaku Zasshi; 2013 Jan; 104(1):15-26. PubMed ID: 23600321
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide.
    Voutsas IF; Anastasopoulou EA; Tzonis P; Papamichail M; Perez SA; Baxevanis CN
    J Immunother Cancer; 2016; 4():75. PubMed ID: 27891225
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tumor vaccines: a role in preventing recurrence in melanoma?
    Sabel MS; Sondak VK
    Am J Clin Dermatol; 2002; 3(9):609-16. PubMed ID: 12444803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Therapeutic vaccines for prostate cancer: recent advances and future directions.
    Strauss J; Madan RA
    Expert Rev Vaccines; 2016 Jul; 15(7):907-14. PubMed ID: 26889831
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The potential role of immunotherapy to treat colorectal cancer.
    Amin M; Lockhart AC
    Expert Opin Investig Drugs; 2015 Mar; 24(3):329-44. PubMed ID: 25519074
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical evaluation of therapeutic cancer vaccines.
    Ogi C; Aruga A
    Hum Vaccin Immunother; 2013 May; 9(5):1049-57. PubMed ID: 23454867
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
    Reardon DA; Mitchell DA
    Semin Immunopathol; 2017 Feb; 39(2):225-239. PubMed ID: 28138787
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic vaccination for cancer immunotherapy: antigen selection and clinical responses.
    Geldmacher A; Freier A; Losch FO; Walden P
    Hum Vaccin; 2011; 7 Suppl():115-9. PubMed ID: 21245666
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Vaccination strategies for solid tumors--fundamentals, limitations, and recent results].
    Atanackovic D
    Ther Umsch; 2004 Jun; 61(6):389-96. PubMed ID: 15253165
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.
    Hofman FM; Stathopoulos A; Kruse CA; Chen TC; Schijns VE
    Anticancer Agents Med Chem; 2010 Jul; 10(6):462-70. PubMed ID: 20879986
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic mRNA-based electrotransfection of autologous dendritic cells and specific antitumor effects against osteosarcoma in rats.
    Yu Z; Qian J; Wu J; Gao J; Zhang M
    Med Oncol; 2012 Dec; 29(5):3440-8. PubMed ID: 22843292
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccines for glioblastoma and high-grade glioma.
    Wheeler CJ; Black KL
    Expert Rev Vaccines; 2011 Jun; 10(6):875-86. PubMed ID: 21692706
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Critical issues in cancer vaccine trial design.
    Clifton GT; Kohrt HE; Peoples GE
    Vaccine; 2015 Dec; 33(51):7386-7392. PubMed ID: 26392010
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
    Sarivalasis A; Boudousquié C; Balint K; Stevenson BJ; Gannon PO; Iancu EM; Rossier L; Martin Lluesma S; Mathevet P; Sempoux C; Coukos G; Dafni U; Harari A; Bassani-Sternberg M; Kandalaft LE
    J Transl Med; 2019 Nov; 17(1):391. PubMed ID: 31771601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Granulocyte-macrophage colony-stimulating factor-based melanoma cell vaccines immunize syngeneic and allogeneic recipients via host dendritic cells.
    Schneeberger A; Lührs P; Kutil R; Steinlein P; Schild H; Schmidt W; Stingl G
    J Immunol; 2003 Nov; 171(10):5180-7. PubMed ID: 14607918
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccines in non-small cell lung cancer: rationale, combination strategies and update on clinical trials.
    De Pas T; Giovannini M; Rescigno M; Catania C; Toffalorio F; Spitaleri G; Delmonte A; Barberis M; Spaggiari L; Solli P; Veronesi G; De Braud F
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):432-43. PubMed ID: 22366114
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials.
    Van Driessche A; Berneman ZN; Van Tendeloo VF
    Oncologist; 2012; 17(2):250-9. PubMed ID: 22291091
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allogeneic CAR Cell Therapy-More Than a Pipe Dream.
    Caldwell KJ; Gottschalk S; Talleur AC
    Front Immunol; 2020; 11():618427. PubMed ID: 33488631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.